Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Tae Jun Song

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6156-8746; OpenAlex author ID A5075335147. Sources: OpenAlex.

Their work

Papers
28 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: 7 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 4 papers

Papers 28

  1. Comparison of clinical features and pancreatic cancer risk between genetic mutations associated versus alcohol associated chronic pancreatitis. First author DOI 10.1016/j.pan.2025.10.011↗
  2. Reply to the Letter to Editor regarding Pancreatic cancer risk in Genetically determined chronic pancreatitis. Co-author DOI 10.1016/j.pan.2025.12.009↗
  3. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  4. A Clinical Score to Identify Individuals at High Risk of Pancreatic Cancer in the General Population. Co-author DOI 10.3390/diagnostics16152390↗
  5. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicen… Co-author DOI 10.1016/j.ejca.2024.114194↗
  6. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  7. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  8. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  9. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  10. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIR… Co-author DOI 10.1016/j.esmoop.2022.100484↗
  11. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  12. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  13. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. Co-author DOI 10.4103/eus-d-21-00049↗
  14. Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed … Co-author DOI 10.5009/gnl210123↗
  15. Corrigendum: Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate… Co-author DOI 10.5009/gnl210123.e↗
  16. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  17. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  18. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  19. A New Era of Endoscopic Ultrasound-Guided Tissue Acquisition for Next-Generation Sequencing for Pancreatic Cancer. Co-author DOI 10.5009/gnl20130↗
  20. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  21. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  22. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
  23. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Co-author DOI 10.1007/s10637-018-0598-5↗
  24. Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Co-author DOI 10.1016/j.jmoldx.2017.09.006↗
  25. Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. Co-author DOI 10.5009/gnl17391↗
  26. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2017.72.3502↗
  27. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  28. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2015.08.048↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dongwook Oh · 13 shared papers, 2016–2026 · strength 2.16
  2. Changhoon Yoo · 16 shared papers, 2017–2026 · strength 1.86
  3. Do Hyun Park · 17 shared papers, 2016–2024 · strength 1.86
  4. Kyu‐pyo Kim · 14 shared papers, 2017–2026 · strength 1.65
  5. Baek‐Yeol Ryoo · 14 shared papers, 2017–2026 · strength 1.65
  6. Dae Wook Hwang · 14 shared papers, 2017–2026 · strength 1.60
  7. Dong Wan Seo · 13 shared papers, 2016–2026 · strength 1.48
  8. Ki Byung Song · 13 shared papers, 2017–2026 · strength 1.47
  9. Song Cheol Kim · 13 shared papers, 2017–2026 · strength 1.47
  10. Sang Soo Lee · 15 shared papers, 2016–2024 · strength 1.41
  11. Jin‐hong Park · 11 shared papers, 2017–2026 · strength 1.27
  12. Myung‐Hwan Kim · 12 shared papers, 2016–2022 · strength 1.10
  13. Woohyung Lee · 5 shared papers, 2020–2026 · strength 0.68
  14. Dong‐Wan Seo · 5 shared papers, 2019–2022 · strength 0.64
  15. Hyehyun Jeong · 3 shared papers, 2024–2026 · strength 0.60
  16. Inkeun Park · 3 shared papers, 2024–2026 · strength 0.60
  17. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  18. Seung‐Mo Hong · 3 shared papers, 2018–2024 · strength 0.38
  19. Jaewon Hyung · 3 shared papers, 2020–2023 · strength 0.38
  20. Gunn Huh · 1 shared paper, 2026 · strength 0.36
  21. Yoonchan Lee · 1 shared paper, 2026 · strength 0.36
  22. Seung Soo Lee · 2 shared papers, 2020–2026 · strength 0.33
  23. Hyunseok Yoon · 2 shared papers, 2023–2024 · strength 0.32
  24. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  25. Hyo Jeong Lee · 1 shared paper, 2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.